Inactivated Rabies-Vectored SARS-CoV-2 Vaccine Provides Long-Term Immune Response Unaffected by Vector Immunity

Scientists screened adjuvants for the highest quality antibody titers, negated the concern of pre-existing rabies-vector immunity, and established its potential as a long-term COVID-19 vaccine.